T cell modifying compounds and uses thereof
US9597357B2 · kind B2 · utility
93Cited by
39References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 10, 2013 |
| Grant date | Mar 21, 2017 |
| Priority date | — |
| Expiry date | Jan 5, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions for modifying T-cells in which PD1 and/or CTLA-4 is repressed and/or inactivated using fusion proteins such as artificial transcription factors and nucleases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.